MRSN vs. ANNX, BMEA, HRTX, KRRO, LXRX, NGNE, CRBP, ESPR, ANRO, and PEPG
Should you be buying Mersana Therapeutics stock or one of its competitors? The main competitors of Mersana Therapeutics include Annexon (ANNX), Biomea Fusion (BMEA), Heron Therapeutics (HRTX), Korro Bio (KRRO), Lexicon Pharmaceuticals (LXRX), Neurogene (NGNE), Corbus Pharmaceuticals (CRBP), Esperion Therapeutics (ESPR), Alto Neuroscience (ANRO), and PepGen (PEPG). These companies are all part of the "pharmaceutical preparations" industry.
Annexon (NASDAQ:ANNX) and Mersana Therapeutics (NASDAQ:MRSN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, community ranking, analyst recommendations, institutional ownership, media sentiment and dividends.
Annexon has a net margin of 0.00% compared to Annexon's net margin of -352.01%. Mersana Therapeutics' return on equity of -66.54% beat Annexon's return on equity.
Annexon has higher earnings, but lower revenue than Mersana Therapeutics. Annexon is trading at a lower price-to-earnings ratio than Mersana Therapeutics, indicating that it is currently the more affordable of the two stocks.
Mersana Therapeutics received 205 more outperform votes than Annexon when rated by MarketBeat users. However, 71.93% of users gave Annexon an outperform vote while only 65.78% of users gave Mersana Therapeutics an outperform vote.
Annexon has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500. Comparatively, Mersana Therapeutics has a beta of 1.61, meaning that its share price is 61% more volatile than the S&P 500.
93.9% of Mersana Therapeutics shares are owned by institutional investors. 19.1% of Annexon shares are owned by company insiders. Comparatively, 12.5% of Mersana Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Annexon presently has a consensus target price of $14.43, suggesting a potential upside of 192.67%. Mersana Therapeutics has a consensus target price of $6.29, suggesting a potential upside of 130.25%. Given Mersana Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Annexon is more favorable than Mersana Therapeutics.
In the previous week, Mersana Therapeutics had 6 more articles in the media than Annexon. MarketBeat recorded 13 mentions for Mersana Therapeutics and 7 mentions for Annexon. Mersana Therapeutics' average media sentiment score of 0.78 beat Annexon's score of 0.50 indicating that Annexon is being referred to more favorably in the media.
Summary
Annexon beats Mersana Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Mersana Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MRSN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MRSN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mersana Therapeutics Competitors List
Related Companies and Tools
